Apollo Eyes J&J Orthopedics at $20 Billion as Shares Rise 0.5%
Updated
Updated · Yahoo Finance · Sep 11
Apollo Eyes J&J Orthopedics at $20 Billion as Shares Rise 0.5%
3 articles · Updated · Yahoo Finance · Sep 11
Summary
J&J shares added 0.5% after hours after Bloomberg reported Apollo Global Management is in talks to buy DePuy Synthes at a valuation near $20 billion.
The discussions are private and may not lead to a deal, with J&J still weighing whether to sell the orthopedics unit or spin it off as a separately listed company.
DePuy Synthes generated about $9.3 billion in 2025 sales—roughly 10% of J&J revenue and nearly 30% of MedTech—and J&J says it would be the largest standalone orthopedics company.
J&J announced the separation in October 2025 and is targeting completion by 2027 as it shifts focus toward faster-growing cardiovascular, surgery and vision businesses.